Greenwich LifeSciences partners with Italian clinical sites for its Phase III FLAMINGO-01 trial evaluating GLSI-100 for breast cancer prevention.Quiver AI SummaryGreenwich LifeSciences, Inc. has announced...
Jaye Thompson, the VP Clinical Reg Affairs of $GLSI ($GLSI), bought 1,000 shares of the company on 11-21-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...
Greenwich LifeSciences updates corporate events and details ongoing Phase III trial of GLSI-100 for breast cancer.Quiver AI SummaryGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company,...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences...